| Autor: |
Alonso Martínez, Luis, Xiques Castillo, Abmel, Calzada Falcón, Victoria, Pérez-Malo Cruz, Marylaine, Leyva Montaña, René, Zamora Barrabí, Minely, Hernández González, Ignacio, León Pérez, Mariela, Arbesú Valdivia, Alejandro |
| Předmět: |
|
| Zdroj: |
Journal of Radioanalytical & Nuclear Chemistry; Oct2014, Vol. 302 Issue 1, p49-56, 8p, 2 Charts, 5 Graphs |
| Abstrakt: |
Yttrium-90-(Y) labeled monoclonal antibodies prepared with a chelating agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), have been used for radioimmunotherapy of cancer. In the present work, the Fab fragment of anti-EGFR monoclonal antibody nimotuzumab was prepared with high purity, integrity and biological activity. The Fab fragment with high specific recognition of EGFR in NCI-H125 human lung adenocarcinoma cells was derivatized with DOTA-NHS applying a simple procedure. DOTA-nimotuzumab Fab fragment was successfully radiolabeled with Y with high radiochemical yield. The in vitro stability of labeled product was optimal over 24 h in buffered solution at 37 °C. Biodistribution and pharmacokinetic studies correctly evaluated the in vivo non-tumor uptake, dosage regimen and excretion pathway in normal Wistar rats. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
